Another study identified that the response to gilteritinib and crenolanib among relapsed FLT3mut AML patients is higher in patients with mutations in NPM1 or DNMT3A and particularly in those with both genes mutated [58,59]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.